Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial
The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood…
The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood…
Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for…
The FDA has backed Kiadis Pharma's lead blood cancer product by granting it the Regenerative Medicine…
Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing…
A new study published in the journal Science Translational Medicine identifies a new treatment strategy…
T-Guard is CEO and co-founder Ypke van Oosterhout’s life work. He told us about the…
Kiadis Pharma has received approval to test in the UK an immune therapy to address…
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's…
MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune…